What’s New?

October 19, 21

החברה הישראלית והשותף האסטרטגי פאדאגיס ערוכים להשקה מסחרית של התרופה בארה"ב חברת עיינה פארמה, הפועלת מירושלים, הודיעה היום כי תרופת ה- Liposomal HCl-Doxorubicin

May 16, 21

Round includes up to $8.4 million investment by the Cystic Fibrosis Foundation Funds will be used to advance the Company's mRNA-altering pipeline for the treatment of cystic fibrosis and other genetic pulmonary diseases

July 20, 20

Nectin Therapeutics, חברה ישראלית המפתחת טיפולים ביולוגיים חדשניים בתחום האימונו-אונקולוגיה, השלימה גיוס של 15 מיליון דולר בסבב B. את הגיוס הובילה Velocity aMoon של קרן אמון, עם השקעה אישית נוספת של מריוס נכט, ובהשתתפות אינטגרה הולדינגס.

July 20, 20

Nectin will use the funding for further development of its next-generation immuno-oncology antibodies that help the immune system fight cancer

November 6, 19

First academic BRIDGE Partnership in Israel aims to translate early-stage research from the Hebrew University (“HU”) of Jerusalem into industrial drug development projects

January 24, 18

Funds will support Phase 2 study of Reltecimod for Acute Kidney Injury; Phase 3 study of Reltecimod for Necrotizing Soft Tissue Infections (“flesh eating bacteria”) ongoing

September 28, 17

Funds will Contribute to Expansion and Development of Integra’s Portfolio, Bringing Hebrew University’s Life Science Innovations to Market

December 9, 14

Jerusalem, Israel, December 8, 2014 - Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem

September 17, 14

The capital is intended for the on-going Phase 2b clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; next interim analysis is expected in Q3 2015; final results expected in Q3 2016

July 24, 14

Funds will be used to advance development of AB103, a novel therapy for the treatment of necrotizing soft tissue infections

February 1, 14

The capital is intended for the completion of the ongoing Phase 2 clinical trial of TL-118, for the treatment of metastatic pancreatic cancer

April 1, 13

Findings published in the Journal of Infectious Diseases

February 1, 13

The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim analysis

November 1, 12

White Plains Hospital is the first U.S. site to offer this innovative treatment to cancer patients

October 1, 12

Integra Holdings closes U.S. $ 7.0 million private financing

May 1, 12

Enrollment has been completed in a Phase 2 study of ladostigil for the treatment of Alzheimer's Disease and results expected in Q4 2012

February 2, 12

Jerusalem Israel - February 13, 2012 - Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.

November 14, 11

Yissum will now maintain 30% holding share in Avraham Pharmaceuticals, which will be transferred to its forthcoming biotech holdings company

October 13, 10

Rehovot Israel - October 13, 2010 - Atox Bio Inc. today announced that it has raised $2.1 million to advance the development of AB103, a clinical stage therapeutic being developed for the treatment of severe bacterial infections and sepsis.

September 1, 10

Rehovot Israel - September 15, 2010 - Atox Bio, a Spin-Off of Yissum, today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103